Current Pharmaceutical Biotechnology
Volume 20, 15 Issues, 2019
ISSN: 1873-4316 (Online)
ISSN: 1389-2010 (Print)
This journal supports open access
ISSN: 1873-4316 (Online)
ISSN: 1389-2010 (Print)
This journal supports open access
Ranking and Category
-
259th of 298 in
Biochemistry & Molecular Biology
-
219th of 267 in
Pharmacology & Pharmacy
Contents
Current Pharmaceutical Biotechnology, Volume 13 - Number 10
Editorial
Editorial: [Hot Topic: Drug Development in Dermatology: New Targets for Old Diseases?]
, 13(10): 1859 - 1860Riccardo G. Borroni
DOI: 10.2174/138920112802273317
Psoriasis, from Pathogenesis to Therapeutic Strategies: IL-21 as a Novel Potential Therapeutic Target
, 13(10): 1861 - 1867Elisabetta Botti, Giulia Spallone, Roberta Caruso, Giovanni Monteleone, Sergio Chimenti and Antonio Costanzo
DOI: 10.2174/138920112802273281
Gene Therapy of Skin Adhesion Disorders (Mini Review)
, 13(10): 1868 - 1876Alessia Cavazza and Fulvio Mavilio
DOI: 10.2174/138920112802273119
Apoptotic Pathways in the Pathogenesis of Pemphigus: Targets for New Therapies
, 13(10): 1877 - 1881Roberta Lotti, Alessandra Marconi and Carlo Pincelli
DOI: 10.2174/138920112802273236
Role of Defensins and Cathelicidin LL37 in Auto-Immune and Auto- Inflammatory Diseases
, 13(10): 1882 - 1897Loredana Frasca and Roberto Lande
DOI: 10.2174/138920112802273155
New Pharmaceutical Concepts for Sebaceous Gland Diseases: Implementing Today’s Pre-Clinical Data into Tomorrow’s Daily Clinical Practice
, 13(10): 1898 - 1913Vasiliki A. Zampeli, Evgenia Makrantonaki, Thrasivoulos Tzellos and Christos C. Zouboulis
DOI: 10.2174/138920112802273173
Editorial
Editorial: [Hot Topic: Antidotes and Rescue Therapies]
, 13(10): 1914 - 1916Richard Y. Wang and Ziad N. Kazzi
DOI: 10.2174/138920112802273164
Acetylcysteine Therapy for Acetaminophen Poisoning
, 13(10): 1917 - 1923Kennon Heard and Jody Green
DOI: 10.2174/138920112802273146
Antidote Control of Aptamer Therapeutics: The Road to a Safer Class of Drug Agents
, 13(10): 1924 - 1934K. M. Bompiani, R. S. Woodruff, R. C. Becker, S. M. Nimjee and B. A. Sullenger
DOI: 10.2174/138920112802273137
Antidotes for Acute Cyanide Poisoning
, 13(10): 1940 - 1948Stephen W. Borron and Frederic J. Baud
DOI: 10.2174/138920112802273182
Calcium and Zinc DTPA Administration for Internal Contamination with Plutonium-238 and Americium-241
, 13(10): 1957 - 1963Ziad N. Kazzi, Alexander Heyl and Johann Ruprecht
DOI: 10.2174/138920112802273308
Legalon® SIL: The Antidote of Choice in Patients with Acute Hepatotoxicity from Amatoxin Poisoning
, 13(10): 1964 - 1970Ulrich Mengs, Ralf - Torsten Pohl and Todd Mitchell
DOI: 10.2174/138920112802273353
Reactive Skin Decontamination Lotion (RSDL) for the Decontamination of Chemical Warfare Agent (CWA) Dermal Exposure
, 13(10): 1971 - 1979M. D. Schwartz, C. G. Hurst, M. A. Kirk, S. J.D. Reedy and E. H. Braue
DOI: 10.2174/138920112802273191
Editorial
Ectopic Lymphoid Neogenesis and Lymphoid Chemokines in Sjogren’s Syndrome: At the Interplay between Chronic Inflammation, Autoimmunity and Lymphomagenesis
, 13(10): 1989 - 1996Michele Bombardieri and Costantino Pitzalis
DOI: 10.2174/138920112802273209
Local Activation and Systemic Dysregulation of T Lymphocytes in Sjögren’s Syndrome
, 13(10): 2009 - 2021Robert Busch, Andreas V. Hadjinicolaou and Frances C. Hall
DOI: 10.2174/138920112802273092
Primary Sjogren’s Syndrome: Time for Prospective Cohorts
, 13(10): 2022 - 2025Jacques-Eric Gottenberg and Xavier Mariette
DOI: 10.2174/138920112802273128
Current and Future Challenges in Primary Sjogren’s Syndrome
, 13(10): 2026 - 2045Arjan Vissink, Hendrika Bootsma, Fred KL Spijkervet, Shen Hu, David T Wong and Cees GM Kallenberg
DOI: 10.2174/138920112802273254
Epigenetics and Sjogren’s Syndrome
, 13(10): 2046 - 2053Christelle Le Dantec, Marie-Michele Varin, Wesley H Brooks, Jacques-Olivier Pers, Pierre Youinou and Yves Renaudineau
DOI: 10.2174/138920112802273326
Primary Sjogren’s Syndrome and the Type I Interferon System
, 13(10): 2054 - 2062Gunnel Nordmark, Maija-Leena Eloranta and Lars Ronnblom
DOI: 10.2174/138920112802273290
Autoantibodies and Sjogren’s Syndrome: A Physiologist’s Perspective
, 13(10): 2063 - 2070Peter M. Smith and Luke J. Dawson
DOI: 10.2174/138920112802273218
B-Lymphocytes Govern the Pathogenesis of Sjogren's Syndrome
, 13(10): 2071 - 2077Pierre Youinou, Alain Saraux and Jacques-Olivier Pers
DOI: 10.2174/138920112802273100
Principles and Applications of Selective Biophysical Methods for Characterization and Comparability Assessment of a Monoclonal Antibody
, 13(10): 2078 - 2101Haripada Maity, Yin Lai, Arvind Srivastava and Joel Goldstein
DOI: 10.2174/138920112802273344
  |
Editor-in-Chief
Davide Prosperi
Department of Biotechnology and Bioscience
University of Milano-Bicocca
Milano
Italy
Biography
View Full Editorial Board
Department of Biotechnology and Bioscience
University of Milano-Bicocca
Milano
Italy
Biography
Biography of Davide Prosperi
Prof. Davide Prosperi is Associate Professor in Biochemistry at the University of Milano Bicocca (Unimib), Department of Biotechnology and Bioscience. Head of the NanoBioLab of Unimib, he is devoted to biomedical and biophysical applications of nanotechnology. In particular, the research activity of Davide Prosperi involves the design, synthesis, functionalization and characterization of colloidal, polymeric and biomimetic nanoparticles for biomedical applications, with particular focus on the diagnosis and treatment of cancer and inflammatory diseases. He is author of over 100 scientific publications. He is one of the author of the patent “Nanoconstructs with pharmacological activity” (n° WO2014013473-A1), and co-founder of the spin-off company inTHEna srl, aiming to design and development of molecules, nanostructures and technologies for biomedical studies and diagnosis, prevention and therapy of human and animal diseases.
About the Journal
For Authors
For Librarians & Readers
Journal History
Current Pharmaceutical Biotechnology was launched in 2000. Dr. Davide Prosperi serves as the Editor-in-Chief of the journal.
Webmaster Contact: info@benthamscience.net